An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): Primary analysis and quality of life outcomes Meeting Abstract
| Authors: | Reni, M.; Riess, H.; O'Reilly, E.; Santoro, A.; Park, J.; Bekaii-Saab, T.; Tempero, M.; Shan, Y.; Macarulla, T.; Van Cutsem, E.; Noel, M.; Berlin, J.; Biankin, A.; Dhani, N.; Frassineti, G.; Goldstein, D.; Romano, A.; Le Bruchec, Y.; Philip, P. |
| Abstract Title: | An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): Primary analysis and quality of life outcomes |
| Meeting Title: | ESMO 21st World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Jul 3-6 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-07-01 |
| Start Page: | mdz154 |
| Language: | English |
| ACCESSION: | WOS:000475860200027 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz154 |
| Notes: | Meeting Abstract: O-001 -- Appears on page iv126 of the abstract book -- Source: Wos |
